| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Factory supply active pharmaceutical intermediate Thymosin alpha 1 Acetate API powder 62304-98-7 C129H215N33O55
5mg/vial, 10 vials per box
raw powder available too
Physical Characters and specifications
Product introduction
Thymosin α1 is a peptide fragment derived from prothymosin alpha, a protein that in humans is encoded by the PTMA gene.
It was the first of the peptides from Thymosin Fraction 5 to be completely sequenced and synthesized. Unlike β thymosins, to which it is genetically and chemically unrelated, thymosin α1 is produced as a 28-amino acid fragment, from a longer, 113-amino acid precursor, prothymosin α.
Thymosin α1 is believed to be a major component of Thymosin Fraction 5 responsible for the activity of that preparation in restoring immune function in animals lacking thymus glands. It has been found to enhance cell-mediated immunity in humans as well as experimental animals.
As of 2009 Thymosin α1 is approved in 35 under-developed or developing countries for the treatment ofHepatitis B and C, and it is also used to boost the immune response in the treatment of other diseases.
){kind=link}